MacroGenics, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses), averaging +22.1% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.34 | $-0.27 | +20.6% | Beat | |
| Q1 FY26 | $-0.57 | $-0.58 | -1.8% | Miss | |
| Q4 FY25 | $-0.42 | $-0.22 | +47.6% | Beat |
Back to MGNX overview · MGNX holders · MGNX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.